Inductive Bio Scores Consecutive Top Rank in Major ADMET Benchmark

According to a recent LinkedIn post from Inductive Bio, the company’s ADMET prediction platform, Beacon, achieved first place in the OpenADMET-ExpansionRx blind challenge, marking its second consecutive top performance in a major ADMET benchmark. The challenge reportedly assessed the ability to predict ADMET properties for more than 2,250 previously unseen compounds from a real drug discovery campaign, emphasizing prospective, real-world performance rather than retrospective datasets.

The post highlights that Beacon’s strong ranking is presented as evidence of how Inductive Bio’s virtual chemistry labs may help drug discovery teams make earlier, higher-confidence decisions regarding safety, dosing, and developability. For investors, repeated success in independent, community-run benchmarks could signal growing technical credibility in the competitive in silico ADMET space, potentially enhancing the company’s positioning with pharmaceutical and biotech customers seeking to de-risk R&D pipelines. If such benchmark performance translates into broader adoption or deeper integration within drug discovery workflows, it could support future revenue growth and strengthen Inductive Bio’s role in the ADMET prediction and virtual drug development ecosystem.